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Abstract
Introduction Hypoxia-inducible factor 1 (HIF-1) alpha and its
downstream targets carbonic anhydrase IX (CAIX) and vascular
endothelial growth factor (VEGF) are key factors in the survival
of proliferating tumor cells in a hypoxic microenvironment. We
studied the expression and prognostic relevance of HIF-1α  and
its downstream targets in phyllodes tumors and fibroadenomas
of the breast.
Methods The expression of HIF-1α , CAIX, VEGF and p53 was
investigated by immunohistochemistry in a group of 37 primary
phyllodes tumors and 30 fibroadenomas with known clinical
follow-up. The tumor microvasculature was visualized by
immunohistochemistry for CD31. Proliferation was assessed by
Ki67 immunostaining and mitotic counts. Being biphasic
tumors, immunoquantification was performed in the stroma and
epithelium.
Results Only two fibroadenomas displayed low-level stromal
HIF-1α  reactivity in the absence of CAIX expression. Stromal
HIF-1α  expression was positively correlated with phyllodes
tumor grade (P = 0.001), with proliferation as measured by Ki67
expression (P < 0.001) and number of mitoses (P < 0.001), with
p53 accumulation (P = 0.003), and with global (P = 0.015) and
hot-spot (P = 0.031) microvessel counts, but not with CAIX
expression. Interestingly, concerted CAIX and HIF-1α
expression was frequently found in morphologically normal
epithelium of phyllodes tumors. The distance from the epithelium
to the nearest microvessels was higher in phyllodes tumors as
compared with in fibroadenomas. Microvessel counts as such
did not differ between fibroadenomas and phyllodes tumors,
however. High expression of VEGF was regularly found in both
tumors, with only a positive relation between stromal VEGF and
grade in phyllodes tumors (P  = 0.016). Stromal HIF-1α
overexpression in phyllodes tumors was predictive of disease-
free survival (P = 0.032).
Conclusion These results indicate that HIF-1α  expression is
associated with diminished disease-free survival and may play
an important role in stromal progression of breast phyllodes
tumors. In view of the absence of stromal CAIX expression in
phyllodes tumors, stromal upregulation of HIF-1α  most probably
arises from hypoxia-independent pathways, with p53
inactivation as one possible cause. In contrast, coexpression of
HIF-1α  and CAIX in the epithelium in phyllodes tumors points to
epithelial hypoxia, most probably caused by relatively distant
blood vessels. On the other hand, HIF-1α  and CAIX seem to be
of minor relevance in breast fibroadenomas.
Introduction
After reaching a critical volume of several cubic millimeters, a
growing tumor becomes increasingly depleted of oxygen and
nutrients, and needs to adapt to its changing microenviron-
ment. In order to survive, tumor cells must develop a vascular
system and adapt their metabolism. A key regulator in this
process is the transcription factor hypoxia-inducible factor 1
(HIF-1) [1], which controls the expression of several target
genes. The protein product of HIF-1 is a heterodimer and con-
sists of two subunits, HIF-1α  and HIF-1β . Under normoxic con-
ditions the HIF-1α  protein is rapidly degraded. O2-dependent
hydroxylation of proline residues in HIF-1α  causes binding of
the von Hippel–Lindau tumor suppressor protein, which leads
to ubiquitilation and subsequent degradation by the
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proteasome [2,3]. Hypoxia inhibits this process, resulting in
upregulation of HIF-1α  and its downstream target genes [4].
On the other hand, hypoxia-independent upregulation of HIF-
1α  may be accomplished by loss of tumor suppressor genes
such as the phosphate and tensin homolog deleted on chro-
mosome 10 (PTEN) [5] and the von Hippel–Lindau tumor sup-
pressor gene VHL [6], by activation of oncogenes like v-Src
[7] and by stimulation by growth factors such as insulin-like
growth factors [8,9] and epidermal growth factor [10].
It has recently been demonstrated that HIF-1α  expression is of
prognostic value in several types of cancer, including breast
cancer [11]. A well-known target of HIF-1α  is the vascular
endothelial growth factor (VEGF) gene [12]. VEGF is a potent
endothelial cell-specific mitogen and is a major participant in
the process of angiogenesis, resulting in the formation of
microvessels. Both VEGF expression [13,14] and microvessel
density [15,16] are established prognosticators in many types
of cancer. Upregulation of carbonic anhydrase 9 (CA9) gene
expression was found to be dependent on HIF-1α  [17]. The
protein product of the CA9  gene, carbonic anhydrase IX
(CAIX), catalyzes the hydration of carbon dioxide to carbonic
acid and contributes to acidification of the surrounding micro-
environment. CAIX is constitutively expressed in cells lining
the alimentary tract [18]. Because of its correlation with low-
ered pO2  in carcinoma of the cervix, CAIX expression is
regarded as an intrinsic marker of hypoxia [19]. Furthermore,
CAIX expression has recently been related to poor outcome in
breast cancer [20]. It therefore seems that HIF-1α  and its
downstream targets play pivotal roles in the development and
progression of cancer.
Breast fibroadenoma and phyllodes tumor are both fibroepi-
thelial tumors; that is, they are composed of an epithelial com-
ponent and a stromal component. The distinction between
both tumors may be difficult [21]. The behavior of fibroadeno-
mas is benign, however, in contrast to phyllodes tumors that
can recur and can even metastasize. In a small number of
cases, fibroadenoma may progress to phyllodes tumor
[22,23]. Little is known of the mechanisms by which these
tumors maintain a steady supply of nutrients as they grow. Few
studies have addressed expression patterns of angiogenic
growth factors in fibroepithelial breast tumors. Expression of
basic fibroblast growth factor (basic FGF), FGF receptor and
VEGF was found at higher levels in stroma of phyllodes tumors
in comparison with fibroadenomas [24]. Unfortunately, no
information on the epithelial component was provided in this
work. Expression patterns of platelet-derived growth factor
(PDGF) and the PDGF receptor suggest the presence of auto-
crine loops in stroma and paracrine stimulation of stroma by
the epithelium [25]. A similar autocrine and paracrine loop has
been described for acidic FGF and FGF receptor 4 in fibroad-
enomas [26]. These studies suggest that stromal proliferation
may be stimulated by secretion of mitogens by the epithelial
compartment. Interestingly, hypoxia may stimulate both FGF
and PDGF expression [27,28]. It would therefore be interest-
ing to evaluate the role of HIF-1α  and its downstream effectors
in the tumorigenesis of biphasic breast tumors.
We therefore studied expression of HIF-1α  and its down-
stream targets VEGF and CAIX in breast phyllodes tumors of
various grades and in fibroadenomas. Furthermore, since HIF-
1α  seems to play a major role in the process of angiogenesis,
we evaluated the microvascular network by counting of CD31-
positive microvessels. Proliferation, as an important functional
end point of various carcinogenic processes, was assessed by
mitotic counts and Ki67 expression. Since HIF-1α  degrada-
tion may be promoted by wild-type p53 [29], we evaluated the
relation between p53 and HIF-1α  expression in phyllodes
tumors. Finally, the prognostic value of HIF-1α , its downstream
effectors and microvessel counts was also assessed for phyl-
lodes tumors.
Materials and methods
Tissue samples
Formaldehyde-fixed and paraffin-embedded tissue samples
were retrieved from the archives of our hospitals. A total of 37
primary phyllodes tumors and 30 fibroadenomas were
acquired. The presence of epithelial proliferative changes was
noted. Phyllodes tumors were graded as benign, borderline or
malignant based on the degree of stromal cellularity, the
degree of stromal overgrowth, the degree of cellular atypia,
invasiveness of the tumor margin and the mitotic activity index
as described previously in detail by Moffat and colleagues
[30]. Mitotic figures were counted using established criteria in
10 consecutive high-power fields at a 400 × magnification
[31]. As the grading of phyllodes tumors may be complicated
by intratumoral heterogeneity, tumors were graded in the most
unfavorable areas provided they comprised at least 10% of the
total tumor area [30]. Clinical data were gathered by studying
medical records.
Immunohistochemistry
Four-micrometer sections were cut and mounted on coated
slides. After deparrafinization and rehydration, sections were
immersed in methanol containing 0.3% hydrogen peroxide to
stop endogenous peroxidase activity. No antigen retrieval was
necessary for CAIX staining.
Antigen retrieval for HIF-1α  was performed in target retrieval
solution (DAKO, Glostrup, Denmark) in a water bath at 97°C
for 45 min, and the remaining antigens were unmasked by
microwaving the slides for 10–15 min in citrate buffer (pH
6.0). The following panel of mouse monoclonal antibodies was
used: VEGF (1:50, R&D Systems, Abingdon, U.K), HIF-1α
(1:500; BDTransduction Laboratories, Lexington, Kentucky,
USA), CAIX (M75, 1:50; kind gift from Dr S Pastorekova (Insti-
tute of Virology, Academy of Science, Bratislava, Slovakia)),
CD31 (JC/70 A, 1:40; DAKO), Ki67 (MIB-1, 1:40; DAKO)
and p53 (DO-7, 1:500; DAKO). VEGF, Ki67 and p53 wereAvailable online http://breast-cancer-research.com/content/7/5/R808
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incubated overnight at 4°C, the incubation time for HIF-1α  and
CAIX was 30 min at room temperature, and CD31 was incu-
bated for 1 hour at room temperature. VEGF, Ki67 and p53
were detected by application of a secondary biotinylated rab-
bit anti-mouse antibody (diluted 1:500; DAKO) followed by
incubation with avidin–biotin-peroxidase complex (1:200 dilu-
tion; DAKO). The Catalyzed Signal Amplification system
(DAKO) was used to detect HIF-1α , CD31 was visualized with
the Ultravision system (Labvision) and CAIX was detected
with the Envision system peroxidase (DAKO). All stainings
were developed with 3,3'-diaminobenzidine tetrahydrochlo-
ride. Counter staining was performed with hematoxylin. Nega-
tive controls were obtained by omitting the primary antibody,
and appropriate positive controls were included throughout.
As fibroadenomas and phyllodes tumors are biphasic tumors,
immunostainings were scored in both stroma and the epithe-
lium. Immunoquantification was performed simultaneously by
two observers (AK and PJvD) behind a double-headed micro-
scope. The percentage of positive staining nuclei for HIF-1α ,
Ki67 and p53 was estimated on a continuous scale, regarding
only homogeneously and darkly stained nuclei as positive.
CAIX expression was scored as positive or negative, scoring
a case positive when membranous staining in any amount was
present. Cytoplasmic VEGF staining was scored semi-quanti-
tatively in four categories from 0 to +++, with category 0
expressing no positive staining, category + showing focal or
diffuse weak staining, and categories ++ and +++ displaying
focal or widespread strong staining, respectively. Counting of
CD31-positive microvessels was performed in the microves-
sel hot-spot in four adjacent fields of vision at 400 × magnifi-
cation as described elsewhere [15,16]. In addition, a global
microvessel density was acquired by counting of vessels in 10
diagonally adjacent fields at a magnification of 400 × from a
random starting point generated semi-automatically by the
QPRODIT interactive digitizing video overlay system (Leica,
Cambridge, UK).
For statistical analysis, stainings for Ki67 and p53 were
divided into high and low using 10% positive staining as the
cut-off [32]. Categories 0 and + staining for VEGF were
grouped as low expression and ++/+++ was stated high, and
microvessel counts were dichotomized using the median
value. As determined by staining of normal breast tissue, pre-
invasive breast lesions and invasive breast cancer, HIF-1α
overexpression was defined as ≥ 1% positive staining nuclei
[33].
The mean shortest distances from microvessels to the epithe-
lial basal membrane were determined with the QPRODIT sys-
tem. Using CD31-stained sections, the distances of the
epithelium to the nearest microvessel were measured
between manually placed markers. Means were calculated
from a minimum of 50 measurements per case with fields of
view selected according to a systematic random sampling
method [34].
Statistical analysis
All statistical analyses were performed with SPSS software
(SPSS, Chicago, IL, USA). Differences in expression of HIF-
1α , of Ki67, of VEGF and of CAIX and the microvessel density
between fibroadenomas and different grades of phyllodes
tumors were investigated by the chi-square test. Correlations
between markers were evaluated using Fisher's exact test. The
clinical endpoint for survival analysis of phyllodes tumors was
local or distant recurrence (disease-free survival). Wide local
excision is the preferred treatment for phyllodes tumors.
Patients treated by primary mastectomy were therefore
excluded from survival analysis since these would bias results
due to strongly reduced chances of recurrence. Kaplan–Meier
curves were plotted and differences between the curves were
evaluated with the log-rank test. P values below 0.05 were
regarded as significant.
Results
Patient characteristics
Thirty fibroadenomas were analyzed. The mean age of patients
was 33.7 ± 10.5 years and the mean tumor size was 1.6 ± 0.6
cm. Ten fibroadenomas (33%) harbored epithelial proliferative
changes.
A total of 18 benign primary phyllodes tumors, eight borderline
primary phyllodes tumors and 11 malignant primary phyllodes
tumors were identified. Epithelial hyperplasia of the ductal
type, mostly focal, was found in 16 cases (43%) and was not
related to grade. The mean age of patients with benign, bor-
derline and malignant phyllodes tumors was 44.4 ± 17.4, 57.9
± 12.8 and 54.3 ± 12.9 years, respectively (P = 0.073). Mean
tumor sizes were 4.8 ± 2.4, 7.1 ± 7.0 and 4.8 ± 2.5 cm for
benign, borderline and malignant phyllodes tumors, respec-
tively (P = 0.924). Patients with phyllodes tumors were older
and had larger tumors (P < 0.001 both) compared with those
patients with fibroadenomas. Five patients with phyllodes
tumors were treated by primary mastectomy, the remainder by
local excision. Excision was incomplete for 13 phyllodes
tumors, whereas for six phyllodes tumors this information
could not be retrieved.
Differences between fibroadenomas and phyllodes 
tumors
Table 1 summarizes the differences in immunostaining
between fibroadenomas and phyllodes tumors. Stromal and
epithelial overexpression of HIF-1α  were found almost exclu-
sively in phyllodes tumors (P = 0.001 and P < 0.001, respec-
tively; Fig. 1b,d). Only two fibroadenomas with low-level
stromal HIF-1α  immunoreactivity (1% and 2% positive nuclei)
were found without concerted CAIX expression. Stromal and
epithelial CAIX expression was only seen in phyllodes tumorsBreast Cancer Research    Vol 7 No 5    Kuijper et al.
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Table 1
Differences in the expression of hypoxia related proteins, microvasculature and proliferation in fibroepithelial breast tumors
Marker Fibroadenoma (n = 30) Phyllodes tumor (n = 37) P valuea
Stroma
HIF-1α 2 (7%) 19 (51%) 0.001
CAIX 0 (0%) 2/36 (6%) 0.497
VEGF 7 (23%) 17 (47%) 0.074
Ki67 1 (3%) 17 (47%) <0.001
Hot-spot microvessel count 13 (43%) 22/35 (63%) 0.140
Global microvessel count 13 (43%) 20/35 (57%) 0.324
p53 0(0%) 7/36(19%) 0.014
Epithelium
HIF-1α 0 (0%) 15/35 (43%) <0.001
CAIX 0 (0%) 9/35 (26%) 0.003
VEGF 22 (73%) 22/36 (61%) 0.432
Ki67 2 (7%) 2/36 (6%) 1.000
p53 0(0%) 0(0%) -
Due to empty blocks, repeated unsuccessful staining attempts or too little epithelium in a malignant tumor, numbers varied slightly for some 
stainings. Dichotomized values were used. aUsing the chi-square test, P values below 0.05 were regarded as significant. HIF-1α  = hypoxia-
inducible factor 1 alpha, CAIX = carbonic anhydrase IX, VEGF = vascular endothelial growth factor.
Figure 1
Examples of immunostaining for hypoxia-inducible factor 1 alpha (HIF-1α ) and carbonic anhydrase IX (CAIX) in breast phyllodes tumors Examples of immunostaining for hypoxia-inducible factor 1 alpha (HIF-1α ) and carbonic anhydrase IX (CAIX) in breast phyllodes tumors. (a) Malig-
nant phyllodes tumor with stromal CAIX expression. (b) Same tumor as (a) with topographically overlapping HIF-1α  overexpression. (c) Benign phyl-
lodes tumor with CAIX-positive staining epithelium. (d) Borderline phyllodes tumor with HIF-1α  overexpression in normal appearing epithelium and in 
subepithelial stroma.Available online http://breast-cancer-research.com/content/7/5/R808
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(Fig. 1a,c). High expression of VEGF was regularly found in
both fibroadenomas and phyllodes tumors. As a result, no dif-
ferences in stromal and epithelial VEGF expression were
found between both tumors.
Many small microvessels were concentrated around the epi-
thelium of fibroadenomas. In phyllodes tumors, microvessels
lacked such a peri-epithelial preference and were distributed
more evenly throughout the tumor. The number of microves-
sels as such, counted by both methods, did not differ signifi-
cantly between fibroadenomas and phyllodes tumors. Indeed,
when regarding microvessel counts on a continuous scale, a
large overlap was observed between fibroadenomas, benign
phyllodes tumors and borderline phyllodes tumors (Fig. 2). In
five fibroadenomas and 10 phyllodes tumors, of which five had
stretches of HIF-1α -positive epithelium, the mean shortest dis-
tance between microvessels and the epithelial basal mem-
brane was 50 ± 11 µm for fibroadenomas and was 83.3 ± 16
µm for phyllodes tumors (P = 0.005). Because of the focal
staining patterns resulting in methodological problems and
low numbers, phyllodes tumors with HIF-1α -negative and HIF-
1α -positive epithelium were not separately analyzed here. Due
to these methodological problems the results should be inter-
preted with caution.
Fibroadenomas and phyllodes tumors did not differ with
regard to the presence of epithelial proliferative changes (P =
0.458).
Differences between phyllodes tumor grades
Correlations between the grade of phyllodes tumor and HIF-
1α  and its downstream targets, microvessels and proliferation
are summarized in Table 2. Stromal HIF-1α  overexpression in
phyllodes tumors was strongly correlated with tumor grade (P
= 0.001), with all malignant tumors displaying overexpression.
Necrosis could be detected in only one malignant phyllodes
tumor, with no typical peri-necrotic HIF-1α  overexpression pat-
tern. Epithelial HIF-1α  overexpression was not related to grade
(P = 0.323). Only two malignant phyllodes tumors displayed
stromal CAIX expression (P = 0.090). Epithelial CAIX expres-
sion was seen more often than stromal CAIX expression, but
was not correlated to grade (P = 0.735). Overexpression of
HIF-1α  and expression of CAIX in the epithelial component
were both not related to hyperplasia and were mostly found in
normal appearing, two-layered epithelium.
A statistically significant difference in the number of microves-
sels was found between grades, both when counted in the
hot-spot and by the global method (P = 0.003 and P = 0.002,
respectively). The number of microvessels was strongly
increased in malignant tumors, as compared with benign and
borderline tumors (Fig. 2). High VEGF expression in the stro-
mal component displayed a positive relation with tumor grade
(P = 0.016).
HIF-1α  expression in both compartments of phyllodes tumors
was not significantly related to tumor size, both with size cut-
off at the median and when used as a continuous variable
(data not shown).
Coexpression of markers
The relations between HIF-1α  expression and its downstream
targets, microvessels and proliferation markers in the stromal
component of fibroepithelial tumors are presented in Table 3.
Since only two cases showed stromal CAIX expression, the
relation between stromal CAIX and stromal HIF-1α  overex-
pression did not reach statistical significance (P = 0.098). The
relation between HIF-1α  overexpression and strong VEGF
expression in stroma reached borderline significance (P  =
0.098). Global (P = 0.015) and hot-spot (P = 0.031) micro-
vessel counts were both related to stromal HIF-1α  overexpres-
sion. Overexpression of HIF-1α  in stroma was correlated with
proliferation as measured by high stromal Ki67 expression (P
< 0.001) and by high mitotic activity index (P < 0.001). Stro-
mal overexpression of HIF-1α  and p53 were also strongly
associated (P = 0.003).
Epithelial HIF-1α  overexpression was related to epithelial
CAIX expression (P = 0.014). There was no relation between
HIF-1α  overexpression in the epithelial component and VEGF
or Ki67 expression. Epithelial HIF-1α  overexpression was
related to increased stromal proliferation (Ki67, P = 0.006;
mitotic activity index, P = 0.004).
Figure 2
Hot-spot microvessel counts in fibroadenomas and phyllodes tumors Hot-spot microvessel counts in fibroadenomas and phyllodes tumors. 
Boxplot showing the large overlap in the numbers of microvessels 
between fibroadenomas (FA), benign phyllodes tumors (BePT) and bor-
derline phyllodes tumors (BoPT) when counted in the hot-spot. MaPT, 
malignant phyllodes tumor.Breast Cancer Research    Vol 7 No 5    Kuijper et al.
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Survival analysis
As already mentioned, patients treated by mastectomy were
excluded from survival analysis. Two patients were lost to fol-
low-up. Ten of the remaining 30 tumors recurred. Most were
local recurrences, but one malignant tumor metastasized to
the lung. By univariate analysis of survival we found an inverse
correlation between stromal HIF-1α  overexpression (P  =
0.032; Fig. 3), tumor grade (P  = 0.039), stromal Ki67
overexpression (P = 0.028) and stromal p53 overexpression
(P < 0.001) and disease-free survival, as presented in Table 4.
HIF-1α  expression did not add to the prognostic power of p53
expression alone. The tumor size (median, 3 cm; P = 0.88),
age (P = 0.36), the mitotic activity index (P = 0.09), the micro-
vessel counts (hot-spot P = 0.54; global P = 0.25), the margin
status (P = 0.23), the VEGF expression (stromal P = 0.96; epi-
thelial P = 0.11), the CAIX expression (stromal P = 0.46; epi-
thelial P = 0.16) and the epithelial HIF-1α  expression (P =
0.76) were not of prognostic relevance. Surprisingly, epithelial
overexpression of Ki67 also had prognostic power (P  =
0.011). This is of no relevance, however, since only two cases
showed epithelial overexpression of Ki67.
Discussion
Evidence is mounting that HIF-1α  and its downstream targets
play pivotal roles in the development and progression of many
types of human cancers. This is the first study evaluating HIF-
1α  and CAIX expression in breast phyllodes tumors. We found
that stromal HIF-1α  overexpression predicts the prognosis of,
and may play an important role in, the stromal progression of
phyllodes tumors. Surprisingly, we regularly found concerted
HIF-1α  and CAIX expression in normal appearing epithelium of
phyllodes tumors. Since only two fibroadenomas displayed
low-level stromal HIF-1α  immunoreactivity and none
expressed CAIX, HIF-1α  and CAIX seem to be of little rele-
vance in these tumors.
HIF-1α  overexpression is induced by hypoxia and by oxygen-
independent mechanisms. In our study, stromal HIF-1α  over-
expression was related to the grade of phyllodes tumors, with
a marked increase from borderline to malignant grade. Benign
and borderline tumors showed comparable levels of HIF-1α
overexpression. We only found two fibroadenomas with low-
level expression of HIF-1α  in the stroma, in agreement with
Zhong and colleagues, who found all their fibroadenomas to
be negative [35]. By clonality analysis we previously demon-
strated that fibroadenomas may progress to phyllodes tumors
by clonal expansion of stroma [22]. Perhaps positive stromal
HIF-1α  staining in a fibroadenoma may reflect an increased
intrinsic capacity to progress to phyllodes tumor. The fibroad-
enomas with stromal HIF-1α  positivity were microscopically
inconspicuous, however.
In several types of cancer, hypoxia-induced HIF-1α  expression
seems to be characterized by a peri-necrotic distribution,
Table 2
Differences in expression of hypoxia-related proteins, microvasculature and proliferation between different grades of phyllodes 
tumors
Marker Phyllodes tumor P valuea
Benign (n = 18) Borderline (n = 8) Malignant (n = 11)
Stroma
HIF-1α 5 (31%) 3 (38%) 11 (100%) 0.001
CAIX 0 (0%) 0 (0%) 2 (18%) 0.090
VEGF 5 (31%) 3 (38%) 9 (82%) 0.016
Ki67 1 (6%) 5 (63%) 11 (100%) <0.001
Hot-spot microvessel count 9/16 (56%) 2 (25%) 11 (100%) 0.003
Global microvessel count 8/16 (50%) 2 (25%) 11 (100%) 0.002
p53 1/18(6%) 1/8(13%) 5/11(46%) 0.025
Epithelium
HIF-1α 7/17 (42%) 2 (25%) 6/10 (60%) 0.323
CAIX 5 (32%) 1/7 (14%) 3/10 (30%) 0.735
VEGF 12 (67%) 5 (63%) 5/10 (50%) 0.684
Ki67 1 (6%) 0 (0%) 1/10 (10%) 0.655
p53 0(0%) 0(0%) 0(0%) -
Due to empty blocks, repeated unsuccessful staining attempts or too little epithelium in a malignant tumor, numbers varied slightly for some 
stainings. Dichotomized values were used. aUsing the chi-square test, P values below 0.05 were regarded as significant. HIF-1α  = hypoxia-
inducible factor 1 alpha, CAIX = carbonic anhydrase IX, VEGF = vascular endothelial growth factor.Available online http://breast-cancer-research.com/content/7/5/R808
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whereas oxygen-independent overexpression results in a dif-
fuse pattern of HIF-1α  immunoreactivity [11,36,37]. Necrosis
was found in the stromal component of only one malignant
phyllodes tumor. Furthermore, stromal HIF-1α  overexpression
was not accompanied by an increase in CAIX expression,
which is regarded as a marker of hypoxia [19]. Indeed, our
group recently showed that, in contrast to homogeneous/dif-
fuse HIF-1α  expression, necrosis-related/focal HIF-1α  expres-
sion is accompanied by CAIX expression [38]. All this
suggests that HIF-1α  upregulation in stroma of phyllodes
tumors is normoxic and may be caused by changes in the stro-
mal expression of oncogenes, tumor suppressor genes or
growth factors. Wild-type p53 has been shown to promote
MDM2-mediated ubiquitination of HIF-1α  [29]. Therefore, p53
inactivation by gene mutation has been implicated in increased
HIF-1α  expression. We showed that aberrant expression of
cell-cycle protein p53 only occurred in the stromal component.
The transition from borderline to malignant phyllodes tumors
was accompanied by a strong increase in stromal p53 expres-
sion, similar to stromal HIF-1α  expression. Furthermore, we
found a significant relation between stromal p53 and HIF-1α
overexpression.
Another candidate for hypoxia-independent upregulation of
HIF-1α  in phyllodes tumors is PDGF. Overexpression of
PDGF was found in 24% of phyllodes tumors, but not in
fibroadenomas [25]. Interestingly, PDGF may induce HIF-1α
expression [39]. Stromal HIF-1α  and p53 expression in phyl-
lodes tumors were predictive of disease-free survival, underlin-
ing the importance of the p53-HIF-1α  axis in it's progression
and clinical behavior.
Epithelial HIF-1α  overexpression in phyllodes tumors was
associated with CAIX expression. This suggests a causative
role for epithelial hypoxia. Fibroadenomas were negative for
CAIX, confirming the results of Bartosova and colleagues [40].
Table 3
Association of hypoxia-inducible factor 1 alpha (HIF-1α ) with its downstream effectors, microvessel counts and proliferation 
markers in stroma of fibroepithelial tumors
HIF-1α P valuea
<1% ≥ 1%
p53
<10% 45 15 0.003
≥ 10% 1 6
Vascular endothelial growth factor
Weak 33 10 0.098
Strong 13 11
Hot-spot microvessel count
<71 25 5 0.031
≥ 71 20 15
Global microvessel count
<86 27 5 0.015
≥ 86 18 15
Carbonic anhydrase IX
Negative 45 19 0.098
Positive 0 2
Ki67
<10% 42 7 <0.001
≥ 10% 4 14
Mitotic activity index
<10 43 8 <0.001
≥ 10 3 13
Dichotomized values were used.
a Fisher's exact test, P values below 0.05 were regarded as significant.Breast Cancer Research    Vol 7 No 5    Kuijper et al.
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The mean distance from microvessels to the epithelium was
significantly higher for phyllodes tumors as compared with
fibroadenomas, suggesting that the hypoxic microenvironment
in the epithelial component of phyllodes tumors is caused by
relatively distant microvessels. Most vessels in phyllodes
tumors were within 150 µm of the epithelial basal membrane,
however, which is a critical distance for necrosis [41]. Still, it
is conceivable that rapidly growing stroma stretches the two-
layered epithelium in such way that it's oxygen supply does not
keep up, resulting in a state of mild hypoxia. Indeed, a previous
report detected CAIX expression 80 µm from the nearest
blood vessel [42], which is comparable with the distance we
found for phyllodes tumors. It is possible that the decreasing
the oxygen gradient between 80 and 150 µm from the nearest
vessel to the epithelium is sufficient to induce HIF-1α  and
CAIX expression.
The scattered foci of positive staining for HIF-1α  and CAIX
suggest the presence of focal mild hypoxia in the epithelial
component. Microenvironmental disturbance of normal tissue
by adjacent malignant disease has been described previously
for HIF-1α  and CAIX [40,43,44]. On the other hand, several
other possible causes exist for epithelial HIF-1α  overexpres-
sion. Epithelial PDGF expression, which is found in most phyl-
lodes tumors [25], may cause HIF-1α  overexpression [39].
Shpitz and colleagues found expression of HER-2/neu in the
epithelium of 61% of phyllodes tumors [45]. It was recently
demonstrated that enhanced HER-2/neu  signaling induces
Table 4
Prognostically significant variables in phyllodes tumors as determined by univariate analysis of disease-free survival (DFS)
Variable Number of patients Number of patients 
with disease (%)
Number of disease-
free patients (%)
Mean DFS (months 
[95% confidence 
interval])
P value Log-rank
p53 stroma
<10% 24 5 (21) 19 (79) 173 (142–204) <0.001 10.97
≥ 10% 6 5 (83) 1 (16) 61 (23–98)
HIF-1α  stroma
<1% 15 3 (20) 12 (80) 180 (146–214) 0.032 4.59
≥ 1% 15 7 (47) 8 (53) 103 (64–142)
Ki67 stroma
<10% 16 4 (25) 12 (75) 176 (145–207) 0.028 4.85
≥ 10% 14 6 (43) 8 (57) 91 (55–127)
Grade
Benign 15 4 (27) 11 (73) 165 (130–200) 0.039 6.48
Borderline 5 1 (20) 4 (80) 140 (86–194)
Malignant 10 5 (50) 5 (50) 71 (32–109)
HIF-1α , hypoxia-inducible factor 1 alpha.
Figure 3
Disease-free survival according to hypoxia-inducible factor 1 alpha  (HIF-1α ) status Disease-free survival according to hypoxia-inducible factor 1 alpha 
(HIF-1α ) status. The Kaplan–Meier survival curve illustrating disease-
free survival for patients with breast phyllodes tumors with high expres-
sion (≥ 1%) versus low expression (<1%) of HIF-1α  in the stromal com-
ponent. Numbers of patients at risk at different time points are 
displayed below the horizontal axis.Available online http://breast-cancer-research.com/content/7/5/R808
R816
HIF-1α  protein expression [46]. Numerous factors interact
with HIF-1 and other as yet unidentified changes in the epithe-
lium of phyllodes tumors may cause HIF-1α  overexpression.
The tumor biological significance of increased epithelial HIF-
1α  and CAIX expression is unclear. Morphologically, the epi-
thelial component was mostly two-layered epithelium without
atypia. Furthermore, clonality studies mostly found the epithe-
lial component of phyllodes tumors to be polyclonal [22,23].
Moreover, phyllodes tumor metastases are composed of
stroma, with only one case described in which the epithelial
component also disseminated, leading to a biphasic metasta-
sis [47]. Finally, epithelial HIF-1α  and CAIX expression are not
predictive of prognosis. It seems therefore that HIF-1α  and
CAIX expression in the epithelium of phyllodes tumors merely
reflects a physiological adaptation to microenvironmental dis-
turbance by rapidly proliferating stroma with lagging peri-epi-
thelial angiogenesis. However, possible upregulation of
growth factors in the epithelium by HIF-1α  may exert an
additional stimulatory force on the stromal component. Indeed,
it has been suggested that in the early stages of phyllodes
tumor development the epithelium secretes mitogens stimulat-
ing the stromal component [48,49]. The presence of such
autocrine and paracrine loops has been described for PDGF/
PDGF receptor [25]. Furthermore, stimulation of the stromal
component by the epithelium was suggested previously by
studying endothelin-1 expression in epithelium of phyllodes
tumors [50]. Interestingly, endothelin-1 turned out to be a tar-
get of HIF-1α  [51].
An abrupt increase in number of microvessels was observed
in malignant phyllodes tumors, coinciding with a strong
increase in stromal overexpression of HIF-1α  from borderline
grade to malignant grade. In contrast with a previous report
[52], we found no difference in microvessel counts between
benign phyllodes tumors and borderline phyllodes tumors. In
addition, when regarding hot-spot and global counts we found
that there was no difference between fibroadenomas, benign
phyllodes tumors and borderline phyllodes tumors. This is in
contrast with a previous report claiming a difference between
fibroadenomas and phyllodes tumors [24]. On the other hand,
Weind and colleagues found a large overlap in microvessel
counts between fibroadenomas and invasive breast cancers,
demonstrating that fibroadenomas are capable of producing
large numbers of microvessels [53]. We found large numbers
of small peri-epithelial microvessels in fibroadenomas respon-
sible for its high numbers of microvessels. It seems that micro-
vessel counts are not helpful in the differentiation between
fibroadenomas and benign phyllodes tumors, which poses the
biggest diagnostic problem.
VEGF expression in fibroadenomas did not differ from that in
phyllodes tumors. Several growth factors such as FGF-4 [54],
PDGF [55] and transforming growth factor beta [56] may stim-
ulate VEGF expression. Expression of FGF [26], PDGF [25]
and transforming growth factor beta [57] have been described
in fibroadenomas and may contribute to HIF-1α -independent
expression of VEGF. In phyllodes tumors, the relation between
VEGF expression and HIF-1α  reached borderline significance.
Although HIF-1α  most probably contributes to VEGF expres-
sion in phyllodes tumors, VEGF expression seems, at least in
part, to be independent from HIF-1α .
In view of its annual incidence of 2.1 cases per 1 million
women [58], we feel that our group of phyllodes tumors is rea-
sonably sized and well composed with all grades present. Still,
future investigations confirming our results in larger series are
warranted. Furthermore, experiments covering a variety of
molecular elements such as DNA microarray techniques may
unravel the complex mechanisms underlying the presumed
nonhypoxic upregulation of HIF-1α  in the stromal component
of phyllodes tumors and its subsequent influence on tumor
progression.
Conclusion
This is the first report on HIF-1α  and CAIX expression in breast
phyllodes tumors. Our results show that HIF-1α  is related to
diminished disease-free survival and may play an important
role in stromal progression of phyllodes tumors. The significant
relation between tumor grade and stromal HIF-1α  overexpres-
sion underlines its importance, with all malignant tumors show-
ing HIF-1α  overexpression. Stromal HIF-1α  overexpression in
phyllodes tumors most probably arises from hypoxia-inde-
pendent pathways, with p53 inactivation as one possible
cause. Surprisingly, the normal-appearing epithelium in
phyllodes tumors frequently displayed HIF-1α  and CAIX
expression. The distance from the nearest vessels to the epi-
thelium was higher in phyllodes tumors as compared with
fibroadenomas and a hypoxic effect seems plausible here,
although the effect is of doubtful biological significance. In
contrast to phyllodes tumors, HIF-1α  seems of minor rele-
vance in the tumorigenesis of fibroadenomas. Considering it's
possible role in progression of the stromal component of phyl-
lodes tumors and the fact that metastases are composed of
stroma, novel therapies targeting HIF-1α  [59] may contribute
to the treatment of disseminated phyllodes tumor, which is
poorly responsive to conventional chemotherapy and
radiotherapy.
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